| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Opioid, kappa | 41 | 2021 | 138 | 9.080 |
Why?
|
| Nucleus Accumbens | 35 | 2021 | 366 | 5.630 |
Why?
|
| Reward | 40 | 2023 | 971 | 3.810 |
Why?
|
| Dynorphins | 13 | 2017 | 82 | 3.430 |
Why?
|
| Cocaine | 32 | 2017 | 958 | 3.300 |
Why?
|
| Fear | 23 | 2024 | 1476 | 2.830 |
Why?
|
| Behavior, Animal | 36 | 2024 | 1878 | 2.760 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 19 | 2020 | 502 | 2.630 |
Why?
|
| Substance Withdrawal Syndrome | 13 | 2020 | 625 | 2.610 |
Why?
|
| Narcotic Antagonists | 20 | 2021 | 585 | 2.420 |
Why?
|
| Self Stimulation | 23 | 2021 | 47 | 2.370 |
Why?
|
| Psychopharmacology | 4 | 2019 | 148 | 2.040 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 7 | 2024 | 108 | 1.800 |
Why?
|
| Rats | 108 | 2024 | 23729 | 1.750 |
Why?
|
| Rats, Sprague-Dawley | 70 | 2020 | 8166 | 1.740 |
Why?
|
| Extinction, Psychological | 10 | 2020 | 371 | 1.670 |
Why?
|
| Tetrahydroisoquinolines | 7 | 2021 | 81 | 1.620 |
Why?
|
| Stress, Psychological | 15 | 2024 | 4477 | 1.490 |
Why?
|
| Morphine | 17 | 2016 | 655 | 1.490 |
Why?
|
| Receptors, Dopamine D1 | 6 | 2021 | 293 | 1.470 |
Why?
|
| Proto-Oncogene Proteins c-fos | 12 | 2016 | 586 | 1.420 |
Why?
|
| Corticotropin-Releasing Hormone | 10 | 2020 | 361 | 1.420 |
Why?
|
| Antidepressive Agents | 12 | 2019 | 2897 | 1.420 |
Why?
|
| Conditioning, Operant | 19 | 2020 | 310 | 1.410 |
Why?
|
| Amygdala | 18 | 2024 | 1353 | 1.380 |
Why?
|
| Anti-Anxiety Agents | 6 | 2019 | 397 | 1.350 |
Why?
|
| Ventral Tegmental Area | 13 | 2017 | 136 | 1.340 |
Why?
|
| Receptors, AMPA | 12 | 2016 | 336 | 1.320 |
Why?
|
| Morphine Dependence | 5 | 2016 | 27 | 1.300 |
Why?
|
| Journal Impact Factor | 2 | 2021 | 153 | 1.260 |
Why?
|
| Animals | 186 | 2024 | 168388 | 1.230 |
Why?
|
| Attention | 9 | 2021 | 2395 | 1.220 |
Why?
|
| Editorial Policies | 4 | 2019 | 458 | 1.180 |
Why?
|
| Diterpenes, Clerodane | 14 | 2011 | 42 | 1.160 |
Why?
|
| Bibliometrics | 3 | 2022 | 352 | 1.110 |
Why?
|
| Septal Nuclei | 4 | 2024 | 85 | 1.100 |
Why?
|
| Dizocilpine Maleate | 8 | 2009 | 172 | 1.080 |
Why?
|
| Dopamine Uptake Inhibitors | 12 | 2017 | 297 | 1.080 |
Why?
|
| Motor Activity | 30 | 2017 | 2710 | 1.070 |
Why?
|
| Periodicals as Topic | 5 | 2020 | 1463 | 1.030 |
Why?
|
| Peer Review, Research | 2 | 2019 | 340 | 1.020 |
Why?
|
| Corpus Striatum | 9 | 2017 | 1235 | 1.020 |
Why?
|
| Brain | 38 | 2023 | 27103 | 1.020 |
Why?
|
| Medial Forebrain Bundle | 8 | 2021 | 43 | 1.010 |
Why?
|
| Cues | 6 | 2020 | 875 | 1.010 |
Why?
|
| Neurosciences | 2 | 2019 | 366 | 0.930 |
Why?
|
| Central Nervous System Stimulants | 8 | 2024 | 1176 | 0.900 |
Why?
|
| Piperidines | 7 | 2021 | 1657 | 0.900 |
Why?
|
| Ketamine | 4 | 2015 | 519 | 0.900 |
Why?
|
| Anxiety Disorders | 6 | 2017 | 2717 | 0.880 |
Why?
|
| Substance-Related Disorders | 15 | 2017 | 4419 | 0.880 |
Why?
|
| Naloxone | 8 | 2013 | 370 | 0.860 |
Why?
|
| Swimming | 10 | 2011 | 208 | 0.850 |
Why?
|
| Conditioning, Classical | 7 | 2024 | 368 | 0.850 |
Why?
|
| Dopamine | 12 | 2017 | 1605 | 0.840 |
Why?
|
| Mice, Inbred C57BL | 24 | 2024 | 22154 | 0.820 |
Why?
|
| Prefrontal Cortex | 12 | 2023 | 2219 | 0.820 |
Why?
|
| Motivation | 6 | 2017 | 2006 | 0.820 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 7 | 2017 | 894 | 0.800 |
Why?
|
| Dose-Response Relationship, Drug | 36 | 2021 | 10764 | 0.790 |
Why?
|
| Mood Disorders | 8 | 2017 | 1127 | 0.790 |
Why?
|
| Nerve Tissue Proteins | 6 | 2018 | 4414 | 0.780 |
Why?
|
| Neurotransmitter Agents | 3 | 2015 | 665 | 0.770 |
Why?
|
| Methylphenidate | 6 | 2024 | 488 | 0.760 |
Why?
|
| Cycloserine | 3 | 2012 | 118 | 0.740 |
Why?
|
| Social Behavior | 6 | 2019 | 1134 | 0.740 |
Why?
|
| Nicotinic Agonists | 2 | 2020 | 265 | 0.730 |
Why?
|
| Disease Models, Animal | 27 | 2020 | 18234 | 0.720 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 602 | 0.710 |
Why?
|
| Self Administration | 14 | 2021 | 390 | 0.690 |
Why?
|
| Diterpenes | 8 | 2007 | 171 | 0.680 |
Why?
|
| Sleep | 5 | 2022 | 4765 | 0.670 |
Why?
|
| Narcotics | 7 | 2013 | 336 | 0.670 |
Why?
|
| Dopamine Agonists | 7 | 2020 | 352 | 0.670 |
Why?
|
| Neurons | 19 | 2023 | 9458 | 0.670 |
Why?
|
| Avoidance Learning | 6 | 2013 | 248 | 0.670 |
Why?
|
| Pyrrolidines | 7 | 2019 | 338 | 0.660 |
Why?
|
| Benzazepines | 5 | 2009 | 310 | 0.650 |
Why?
|
| Nicotine | 4 | 2020 | 680 | 0.650 |
Why?
|
| Depressive Disorder | 6 | 2017 | 3728 | 0.640 |
Why?
|
| Bromocriptine | 5 | 2002 | 93 | 0.620 |
Why?
|
| Psychotropic Drugs | 5 | 2009 | 888 | 0.610 |
Why?
|
| Benzeneacetamides | 6 | 2013 | 36 | 0.590 |
Why?
|
| Excitatory Amino Acid Antagonists | 6 | 2010 | 448 | 0.590 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 181 | 0.580 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2019 | 177 | 0.580 |
Why?
|
| Neuropharmacology | 1 | 2017 | 20 | 0.580 |
Why?
|
| Naltrexone | 9 | 2016 | 317 | 0.570 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 2019 | 20 | 0.570 |
Why?
|
| Microglia | 3 | 2024 | 1357 | 0.570 |
Why?
|
| Telemetry | 1 | 2018 | 199 | 0.570 |
Why?
|
| Brain Chemistry | 3 | 2005 | 959 | 0.560 |
Why?
|
| Autistic Disorder | 2 | 2019 | 1220 | 0.560 |
Why?
|
| Amphetamines | 2 | 2015 | 143 | 0.560 |
Why?
|
| Male | 125 | 2024 | 360621 | 0.550 |
Why?
|
| Depression | 12 | 2015 | 8122 | 0.540 |
Why?
|
| Drug-Seeking Behavior | 2 | 2016 | 46 | 0.530 |
Why?
|
| Reaction Time | 10 | 2021 | 2080 | 0.530 |
Why?
|
| Rats, Long-Evans | 6 | 2024 | 383 | 0.520 |
Why?
|
| Receptors, GABA-A | 4 | 2021 | 623 | 0.500 |
Why?
|
| Mice | 45 | 2024 | 81474 | 0.500 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2019 | 2508 | 0.500 |
Why?
|
| Desipramine | 4 | 2008 | 182 | 0.490 |
Why?
|
| Simplexvirus | 9 | 2015 | 803 | 0.480 |
Why?
|
| Stress Disorders, Post-Traumatic | 7 | 2024 | 4579 | 0.480 |
Why?
|
| Tobacco Use Disorder | 1 | 2020 | 703 | 0.470 |
Why?
|
| Mental Disorders | 7 | 2019 | 6839 | 0.460 |
Why?
|
| Cocaine-Related Disorders | 2 | 2015 | 461 | 0.450 |
Why?
|
| Immunity | 1 | 2019 | 997 | 0.440 |
Why?
|
| Neuronal Plasticity | 4 | 2018 | 1435 | 0.440 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 2549 | 0.440 |
Why?
|
| Electric Stimulation | 15 | 2015 | 1735 | 0.430 |
Why?
|
| Publishing | 1 | 2020 | 833 | 0.430 |
Why?
|
| Gene Transfer Techniques | 10 | 2015 | 1205 | 0.430 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2021 | 485 | 0.420 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 1342 | 0.420 |
Why?
|
| Maze Learning | 6 | 2015 | 482 | 0.410 |
Why?
|
| Compulsive Behavior | 1 | 2013 | 117 | 0.410 |
Why?
|
| Maternal Exposure | 1 | 2019 | 1061 | 0.410 |
Why?
|
| Microinjections | 8 | 2011 | 321 | 0.410 |
Why?
|
| Genetic Vectors | 12 | 2015 | 3393 | 0.400 |
Why?
|
| Locomotion | 5 | 2021 | 388 | 0.390 |
Why?
|
| Antimetabolites | 1 | 2012 | 128 | 0.390 |
Why?
|
| Salvia | 3 | 2008 | 13 | 0.390 |
Why?
|
| Phencyclidine | 4 | 1996 | 60 | 0.390 |
Why?
|
| Learning | 6 | 2017 | 1740 | 0.390 |
Why?
|
| Fetus | 1 | 2019 | 1864 | 0.380 |
Why?
|
| Hippocampus | 4 | 2022 | 3763 | 0.380 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2011 | 60 | 0.380 |
Why?
|
| Depressive Disorder, Major | 4 | 2023 | 4760 | 0.370 |
Why?
|
| Synaptic Transmission | 9 | 2018 | 1172 | 0.370 |
Why?
|
| Inflammation | 3 | 2021 | 10760 | 0.370 |
Why?
|
| Circadian Rhythm | 4 | 2019 | 2574 | 0.360 |
Why?
|
| Excitatory Amino Acid Agonists | 2 | 2012 | 144 | 0.360 |
Why?
|
| Mental Health | 2 | 2022 | 3248 | 0.360 |
Why?
|
| Behavior, Addictive | 5 | 2012 | 462 | 0.360 |
Why?
|
| Frontal Lobe | 2 | 2013 | 1420 | 0.360 |
Why?
|
| Models, Psychological | 1 | 2014 | 828 | 0.350 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 2870 | 0.350 |
Why?
|
| Mammals | 3 | 2022 | 1132 | 0.340 |
Why?
|
| Corticosterone | 3 | 2024 | 305 | 0.340 |
Why?
|
| Thalamus | 2 | 2013 | 1044 | 0.340 |
Why?
|
| Drug Discovery | 2 | 2019 | 1054 | 0.340 |
Why?
|
| Long-Term Potentiation | 4 | 2009 | 293 | 0.330 |
Why?
|
| Executive Function | 2 | 2024 | 1389 | 0.330 |
Why?
|
| Sex Characteristics | 2 | 2019 | 2637 | 0.330 |
Why?
|
| Cannabis | 1 | 2015 | 440 | 0.330 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2009 | 483 | 0.320 |
Why?
|
| Hyperkinesis | 1 | 2009 | 89 | 0.320 |
Why?
|
| Neurogenesis | 1 | 2015 | 862 | 0.310 |
Why?
|
| Lovastatin | 1 | 2008 | 116 | 0.310 |
Why?
|
| Neuropeptides | 1 | 2014 | 944 | 0.310 |
Why?
|
| Cytidine | 2 | 2012 | 65 | 0.300 |
Why?
|
| Valproic Acid | 2 | 2012 | 443 | 0.300 |
Why?
|
| Veterans | 1 | 2022 | 2647 | 0.300 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 3701 | 0.300 |
Why?
|
| Electroencephalography | 7 | 2024 | 6224 | 0.300 |
Why?
|
| Raphe Nuclei | 1 | 2007 | 103 | 0.290 |
Why?
|
| Fluoxetine | 2 | 2008 | 733 | 0.290 |
Why?
|
| Psychomotor Performance | 4 | 2015 | 1879 | 0.280 |
Why?
|
| Electroshock | 1 | 2007 | 121 | 0.280 |
Why?
|
| Lithium | 3 | 2007 | 596 | 0.280 |
Why?
|
| Gene Expression Regulation | 14 | 2016 | 11900 | 0.280 |
Why?
|
| Anesthetics, Local | 2 | 2011 | 997 | 0.280 |
Why?
|
| Internet | 1 | 2019 | 3094 | 0.280 |
Why?
|
| Behavioral Research | 1 | 2007 | 52 | 0.280 |
Why?
|
| Cannabinoids | 2 | 2022 | 172 | 0.280 |
Why?
|
| Nomifensine | 2 | 1996 | 14 | 0.280 |
Why?
|
| Analysis of Variance | 11 | 2012 | 6231 | 0.270 |
Why?
|
| Immunity, Innate | 1 | 2019 | 3060 | 0.270 |
Why?
|
| Cognition | 4 | 2024 | 6987 | 0.270 |
Why?
|
| Affect | 3 | 2017 | 1485 | 0.270 |
Why?
|
| Anxiety | 4 | 2021 | 4571 | 0.270 |
Why?
|
| Neuroglia | 2 | 2014 | 955 | 0.260 |
Why?
|
| Psychiatry | 1 | 2018 | 1690 | 0.260 |
Why?
|
| Formaldehyde | 2 | 2020 | 358 | 0.260 |
Why?
|
| Central Nervous System Diseases | 1 | 2010 | 520 | 0.250 |
Why?
|
| Diltiazem | 1 | 2006 | 131 | 0.250 |
Why?
|
| Time Factors | 23 | 2015 | 39974 | 0.250 |
Why?
|
| Limbic System | 3 | 2006 | 419 | 0.250 |
Why?
|
| Memory | 4 | 2024 | 2187 | 0.250 |
Why?
|
| Autoimmune Diseases | 2 | 2014 | 2248 | 0.250 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 9534 | 0.250 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2005 | 114 | 0.250 |
Why?
|
| Humans | 70 | 2024 | 761326 | 0.240 |
Why?
|
| Uridine | 1 | 2005 | 142 | 0.240 |
Why?
|
| Signal Transduction | 10 | 2020 | 23427 | 0.230 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2013 | 1491 | 0.230 |
Why?
|
| Lipopolysaccharides | 3 | 2021 | 2206 | 0.220 |
Why?
|
| Choice Behavior | 2 | 2007 | 824 | 0.220 |
Why?
|
| Leadership | 1 | 2013 | 1385 | 0.220 |
Why?
|
| Morphinans | 2 | 2013 | 27 | 0.210 |
Why?
|
| Electromagnetic Fields | 1 | 2005 | 296 | 0.210 |
Why?
|
| Analgesics, Opioid | 7 | 2014 | 3801 | 0.210 |
Why?
|
| Drug Interactions | 6 | 2011 | 1415 | 0.210 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 694 | 0.200 |
Why?
|
| DNA, Circular | 1 | 2022 | 97 | 0.200 |
Why?
|
| Cytokines | 4 | 2024 | 7390 | 0.200 |
Why?
|
| Glutamates | 1 | 2003 | 389 | 0.200 |
Why?
|
| Neostriatum | 1 | 2003 | 246 | 0.200 |
Why?
|
| Guanidines | 2 | 2013 | 192 | 0.200 |
Why?
|
| Gene Targeting | 1 | 2005 | 838 | 0.200 |
Why?
|
| Epilepsy | 1 | 2017 | 3290 | 0.200 |
Why?
|
| Hypokinesia | 1 | 2001 | 23 | 0.200 |
Why?
|
| Hypothalamic Area, Lateral | 2 | 2011 | 108 | 0.200 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 208 | 0.200 |
Why?
|
| Dopamine Agents | 2 | 2021 | 189 | 0.190 |
Why?
|
| Freezing Reaction, Cataleptic | 2 | 2015 | 41 | 0.190 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 680 | 0.190 |
Why?
|
| Pandemics | 2 | 2022 | 8635 | 0.190 |
Why?
|
| Stress, Physiological | 1 | 2008 | 1403 | 0.190 |
Why?
|
| Research Design | 1 | 2017 | 6178 | 0.190 |
Why?
|
| Drug Synergism | 5 | 2008 | 1757 | 0.190 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2021 | 69 | 0.190 |
Why?
|
| Behavior | 1 | 2004 | 540 | 0.180 |
Why?
|
| Gene Expression | 6 | 2019 | 7582 | 0.180 |
Why?
|
| Ion Channels | 1 | 2005 | 1040 | 0.180 |
Why?
|
| Echo-Planar Imaging | 1 | 2005 | 663 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 614 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2012 | 1392 | 0.180 |
Why?
|
| Transfection | 2 | 2005 | 5776 | 0.170 |
Why?
|
| Antipsychotic Agents | 3 | 2009 | 3067 | 0.170 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2020 | 158 | 0.170 |
Why?
|
| Rodentia | 1 | 2021 | 262 | 0.170 |
Why?
|
| Opioid-Related Disorders | 2 | 2012 | 2160 | 0.170 |
Why?
|
| Glutamic Acid | 4 | 2017 | 1176 | 0.170 |
Why?
|
| Kainic Acid | 3 | 2015 | 203 | 0.170 |
Why?
|
| Receptors, GABA | 1 | 2021 | 313 | 0.170 |
Why?
|
| Benzamides | 2 | 2019 | 1370 | 0.170 |
Why?
|
| Dietary Fats | 1 | 2007 | 1994 | 0.160 |
Why?
|
| RNA, Messenger | 6 | 2018 | 12787 | 0.160 |
Why?
|
| Scalp | 1 | 2022 | 389 | 0.160 |
Why?
|
| Methamphetamine | 1 | 2021 | 165 | 0.160 |
Why?
|
| Immobility Response, Tonic | 2 | 2011 | 13 | 0.160 |
Why?
|
| Mice, Knockout | 8 | 2017 | 14409 | 0.160 |
Why?
|
| Isoquinolines | 2 | 2008 | 352 | 0.160 |
Why?
|
| Infusions, Intraventricular | 2 | 2015 | 32 | 0.160 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2024 | 726 | 0.160 |
Why?
|
| Evoked Potentials | 1 | 2024 | 1037 | 0.160 |
Why?
|
| Hypothalamus | 2 | 2014 | 999 | 0.160 |
Why?
|
| Acetamides | 2 | 2012 | 256 | 0.150 |
Why?
|
| CREB-Binding Protein | 2 | 2016 | 148 | 0.150 |
Why?
|
| Drug Administration Routes | 2 | 2011 | 150 | 0.150 |
Why?
|
| DNA, Viral | 1 | 2005 | 2201 | 0.150 |
Why?
|
| Ligands | 3 | 2013 | 3271 | 0.150 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1379 | 0.150 |
Why?
|
| Gender Identity | 2 | 2022 | 766 | 0.150 |
Why?
|
| Search Engine | 1 | 2019 | 143 | 0.150 |
Why?
|
| Light | 2 | 2020 | 1351 | 0.150 |
Why?
|
| Excitatory Postsynaptic Potentials | 4 | 2012 | 369 | 0.150 |
Why?
|
| Reinforcement Schedule | 3 | 2012 | 123 | 0.150 |
Why?
|
| Sleep Deprivation | 1 | 2024 | 843 | 0.150 |
Why?
|
| Pregnancy | 7 | 2023 | 29858 | 0.140 |
Why?
|
| Poly I-C | 1 | 2017 | 112 | 0.140 |
Why?
|
| Opioid Peptides | 1 | 2017 | 37 | 0.140 |
Why?
|
| Herpesvirus 1, Human | 1 | 2003 | 753 | 0.140 |
Why?
|
| Schizophrenia | 2 | 2017 | 6937 | 0.140 |
Why?
|
| Pain | 5 | 2014 | 5077 | 0.140 |
Why?
|
| Racemases and Epimerases | 1 | 2017 | 114 | 0.140 |
Why?
|
| Animals, Newborn | 2 | 2017 | 2678 | 0.140 |
Why?
|
| Receptors, Opioid, delta | 3 | 2013 | 48 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 370 | 0.130 |
Why?
|
| Brain Diseases | 1 | 2005 | 1545 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2019 | 590 | 0.130 |
Why?
|
| Dominance-Subordination | 1 | 2015 | 26 | 0.130 |
Why?
|
| Autophagy | 1 | 2024 | 1321 | 0.130 |
Why?
|
| Acoustic Stimulation | 1 | 2020 | 1235 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 3704 | 0.130 |
Why?
|
| Benzodiazepines | 2 | 2012 | 1132 | 0.120 |
Why?
|
| Blotting, Western | 5 | 2008 | 5034 | 0.120 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2015 | 415 | 0.120 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 916 | 0.120 |
Why?
|
| Interferon Inducers | 1 | 2014 | 25 | 0.120 |
Why?
|
| Female | 24 | 2024 | 392485 | 0.120 |
Why?
|
| Seizures | 2 | 2008 | 2956 | 0.120 |
Why?
|
| Salicylamides | 1 | 1994 | 33 | 0.120 |
Why?
|
| Electrodes, Implanted | 4 | 2009 | 840 | 0.120 |
Why?
|
| Freund's Adjuvant | 1 | 2014 | 148 | 0.120 |
Why?
|
| Photic Stimulation | 3 | 2021 | 1985 | 0.120 |
Why?
|
| Neuropsychological Tests | 3 | 2021 | 7045 | 0.120 |
Why?
|
| Body Temperature | 1 | 2017 | 782 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2001 | 2913 | 0.110 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2015 | 89 | 0.110 |
Why?
|
| Models, Neurological | 3 | 2010 | 1767 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2015 | 157 | 0.110 |
Why?
|
| Serotonin | 3 | 2007 | 1041 | 0.110 |
Why?
|
| Melatonin | 1 | 2019 | 669 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3244 | 0.110 |
Why?
|
| Astrocytes | 2 | 2012 | 1346 | 0.110 |
Why?
|
| Psychological Tests | 1 | 2015 | 640 | 0.110 |
Why?
|
| Neuralgia | 1 | 2020 | 614 | 0.110 |
Why?
|
| Biophysics | 2 | 2011 | 380 | 0.110 |
Why?
|
| Tetrazoles | 1 | 1999 | 910 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2021 | 1140 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2015 | 591 | 0.100 |
Why?
|
| Neural Inhibition | 1 | 2017 | 590 | 0.100 |
Why?
|
| Random Allocation | 1 | 2017 | 2389 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2013 | 174 | 0.100 |
Why?
|
| Piperazines | 2 | 2008 | 2519 | 0.100 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 225 | 0.100 |
Why?
|
| Microdialysis | 2 | 2017 | 161 | 0.100 |
Why?
|
| Diazepam | 2 | 2010 | 215 | 0.100 |
Why?
|
| Point Mutation | 2 | 2012 | 1595 | 0.100 |
Why?
|
| Clozapine | 3 | 2016 | 506 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 74 | 0.100 |
Why?
|
| Arousal | 3 | 2022 | 1166 | 0.100 |
Why?
|
| Marijuana Abuse | 1 | 2015 | 411 | 0.100 |
Why?
|
| Cyclic AMP | 2 | 2009 | 1462 | 0.100 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2011 | 127 | 0.090 |
Why?
|
| Impulsive Behavior | 1 | 2014 | 346 | 0.090 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 2007 | 370 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10431 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2008 | 8312 | 0.090 |
Why?
|
| Interpersonal Relations | 2 | 2017 | 1436 | 0.090 |
Why?
|
| Encephalitis | 1 | 2014 | 438 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1886 | 0.090 |
Why?
|
| Implosive Therapy | 1 | 2012 | 125 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2019 | 1127 | 0.090 |
Why?
|
| Amphetamine | 3 | 2009 | 224 | 0.090 |
Why?
|
| Neural Pathways | 6 | 2023 | 3057 | 0.090 |
Why?
|
| Triazines | 1 | 2012 | 311 | 0.090 |
Why?
|
| Sex Factors | 3 | 2021 | 10551 | 0.090 |
Why?
|
| Dependovirus | 1 | 2015 | 715 | 0.090 |
Why?
|
| Catalepsy | 1 | 2009 | 31 | 0.090 |
Why?
|
| Structure-Activity Relationship | 7 | 2011 | 3076 | 0.090 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2015 | 600 | 0.090 |
Why?
|
| Receptors, Glutamate | 1 | 2010 | 228 | 0.080 |
Why?
|
| Rats, Inbred Strains | 3 | 2003 | 2090 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2009 | 112 | 0.080 |
Why?
|
| Bipolar Disorder | 4 | 2012 | 5091 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2010 | 174 | 0.080 |
Why?
|
| Brain Tissue Transplantation | 1 | 2009 | 81 | 0.080 |
Why?
|
| Haloperidol | 2 | 2009 | 389 | 0.080 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2009 | 137 | 0.080 |
Why?
|
| TRPC Cation Channels | 1 | 2009 | 111 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 2 | 2012 | 412 | 0.080 |
Why?
|
| Child | 5 | 2023 | 80156 | 0.080 |
Why?
|
| Epinephrine | 1 | 2011 | 792 | 0.080 |
Why?
|
| Animal Experimentation | 1 | 2008 | 46 | 0.080 |
Why?
|
| HIV-1 | 1 | 2005 | 6860 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2022 | 3979 | 0.070 |
Why?
|
| Biogenic Monoamines | 1 | 2007 | 50 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2015 | 9319 | 0.070 |
Why?
|
| Genes, fos | 1 | 2008 | 175 | 0.070 |
Why?
|
| Ethers | 1 | 2007 | 73 | 0.070 |
Why?
|
| Biomedical Research | 2 | 2017 | 3429 | 0.070 |
Why?
|
| Synapses | 3 | 2013 | 1769 | 0.070 |
Why?
|
| Furans | 1 | 2008 | 200 | 0.070 |
Why?
|
| Resilience, Psychological | 1 | 2015 | 788 | 0.070 |
Why?
|
| Association Learning | 2 | 2005 | 221 | 0.070 |
Why?
|
| Alcohols | 1 | 2007 | 94 | 0.070 |
Why?
|
| Serial Learning | 1 | 2007 | 42 | 0.070 |
Why?
|
| Efferent Pathways | 1 | 2007 | 165 | 0.070 |
Why?
|
| Euphoria | 1 | 2007 | 65 | 0.070 |
Why?
|
| Prosencephalon | 1 | 2009 | 305 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2008 | 18962 | 0.070 |
Why?
|
| GTP Cyclohydrolase | 1 | 2006 | 47 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6210 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 1753 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2011 | 1688 | 0.070 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 311 | 0.070 |
Why?
|
| Species Specificity | 3 | 2024 | 2419 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2006 | 882 | 0.070 |
Why?
|
| Dopamine Antagonists | 2 | 2020 | 288 | 0.070 |
Why?
|
| Receptors, Dopamine | 1 | 2007 | 296 | 0.070 |
Why?
|
| Disease | 1 | 2011 | 672 | 0.070 |
Why?
|
| Transgenes | 2 | 2001 | 1009 | 0.070 |
Why?
|
| Depression, Chemical | 1 | 2005 | 184 | 0.070 |
Why?
|
| Adult | 10 | 2024 | 221122 | 0.060 |
Why?
|
| Neurobiology | 1 | 2007 | 137 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2007 | 489 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 2152 | 0.060 |
Why?
|
| Models, Animal | 2 | 2020 | 2112 | 0.060 |
Why?
|
| Terrorism | 1 | 2008 | 211 | 0.060 |
Why?
|
| Tegmentum Mesencephali | 2 | 1999 | 59 | 0.060 |
Why?
|
| Pain, Intractable | 1 | 2006 | 132 | 0.060 |
Why?
|
| Plant Leaves | 1 | 2005 | 150 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 1809 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 10191 | 0.060 |
Why?
|
| Acute Disease | 1 | 2015 | 7238 | 0.060 |
Why?
|
| Social Dominance | 1 | 2024 | 39 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 1 | 2006 | 242 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 1141 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2007 | 554 | 0.060 |
Why?
|
| Drug Design | 1 | 2009 | 1050 | 0.060 |
Why?
|
| Gonadal Hormones | 1 | 2023 | 30 | 0.060 |
Why?
|
| Protein Binding | 2 | 2013 | 9351 | 0.060 |
Why?
|
| Colchicine | 1 | 2005 | 260 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2007 | 803 | 0.060 |
Why?
|
| Extracellular Space | 1 | 2005 | 563 | 0.060 |
Why?
|
| Gout Suppressants | 1 | 2005 | 177 | 0.050 |
Why?
|
| Physical Stimulation | 1 | 2005 | 518 | 0.050 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2002 | 36 | 0.050 |
Why?
|
| Research Personnel | 1 | 2008 | 588 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2010 | 1198 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2005 | 431 | 0.050 |
Why?
|
| Cell Count | 1 | 2007 | 1835 | 0.050 |
Why?
|
| Lac Operon | 1 | 2003 | 237 | 0.050 |
Why?
|
| Immobilization | 1 | 2003 | 227 | 0.050 |
Why?
|
| PC12 Cells | 1 | 2003 | 317 | 0.050 |
Why?
|
| Carbon | 1 | 2006 | 665 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 8592 | 0.050 |
Why?
|
| Pain Threshold | 1 | 2006 | 603 | 0.050 |
Why?
|
| Molecular Conformation | 3 | 2011 | 545 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2012 | 1906 | 0.050 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2002 | 29 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2019 | 1337 | 0.050 |
Why?
|
| Drug Implants | 1 | 2003 | 230 | 0.050 |
Why?
|
| Entorhinal Cortex | 1 | 2024 | 287 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2008 | 2048 | 0.050 |
Why?
|
| Neurites | 1 | 2024 | 391 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 17640 | 0.050 |
Why?
|
| Receptors, Adrenergic | 1 | 2001 | 155 | 0.050 |
Why?
|
| Cerebral Cortex | 2 | 2011 | 5776 | 0.050 |
Why?
|
| Antigens | 1 | 2007 | 1446 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 13446 | 0.050 |
Why?
|
| Kinetics | 2 | 2013 | 6374 | 0.050 |
Why?
|
| Rats, Wistar | 3 | 2017 | 1846 | 0.050 |
Why?
|
| Lighting | 1 | 2003 | 211 | 0.050 |
Why?
|
| Peptides | 1 | 2013 | 4342 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 2 | 2017 | 927 | 0.050 |
Why?
|
| Nerve Net | 1 | 2012 | 2288 | 0.040 |
Why?
|
| Serine | 2 | 2017 | 829 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 2413 | 0.040 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 1262 | 0.040 |
Why?
|
| Equipment and Supplies | 1 | 2003 | 273 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 10498 | 0.040 |
Why?
|
| Aging | 3 | 2004 | 8704 | 0.040 |
Why?
|
| Presynaptic Terminals | 1 | 2002 | 302 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 6309 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1704 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4567 | 0.040 |
Why?
|
| Adaptation, Physiological | 2 | 2006 | 1301 | 0.040 |
Why?
|
| CHO Cells | 3 | 2006 | 1389 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2003 | 962 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2007 | 1598 | 0.040 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2011 | 195 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2024 | 525 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2001 | 862 | 0.040 |
Why?
|
| Sleep, REM | 1 | 2022 | 594 | 0.040 |
Why?
|
| Evoked Potentials, Visual | 1 | 2021 | 417 | 0.040 |
Why?
|
| Feeding Behavior | 2 | 2008 | 3187 | 0.040 |
Why?
|
| Biological Transport | 2 | 2013 | 2090 | 0.040 |
Why?
|
| Cricetinae | 3 | 2006 | 2427 | 0.040 |
Why?
|
| Neurotensin | 1 | 2018 | 60 | 0.040 |
Why?
|
| Tachykinins | 1 | 2018 | 77 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2223 | 0.040 |
Why?
|
| Protein Kinase C-delta | 1 | 2018 | 114 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 15835 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2007 | 2858 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2000 | 563 | 0.040 |
Why?
|
| Neurosecretory Systems | 1 | 1998 | 223 | 0.040 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2016 | 18 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7999 | 0.030 |
Why?
|
| Yohimbine | 1 | 2016 | 62 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 3710 | 0.030 |
Why?
|
| Lactic Acid | 2 | 2013 | 1137 | 0.030 |
Why?
|
| Somatostatin | 1 | 2018 | 447 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2009 | 3552 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2015 | 64645 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2005 | 5439 | 0.030 |
Why?
|
| Hierarchy, Social | 1 | 2014 | 24 | 0.030 |
Why?
|
| Wakefulness | 1 | 2022 | 1265 | 0.030 |
Why?
|
| Recurrence | 1 | 2007 | 8470 | 0.030 |
Why?
|
| Raclopride | 1 | 1994 | 101 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2007 | 4120 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3889 | 0.030 |
Why?
|
| Ketoprofen | 1 | 2013 | 7 | 0.030 |
Why?
|
| Alcoholism | 1 | 2005 | 1973 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2000 | 1968 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2022 | 12329 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2023 | 2163 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2018 | 1134 | 0.030 |
Why?
|
| Exploratory Behavior | 2 | 2009 | 279 | 0.030 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2013 | 66 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2013 | 146 | 0.030 |
Why?
|
| Enkephalins | 1 | 1993 | 139 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 1993 | 24 | 0.030 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 2013 | 58 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2000 | 957 | 0.030 |
Why?
|
| Brain Mapping | 2 | 2007 | 6626 | 0.030 |
Why?
|
| Interneurons | 1 | 2018 | 593 | 0.030 |
Why?
|
| Galantamine | 1 | 1993 | 33 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2015 | 555 | 0.030 |
Why?
|
| Microdissection | 1 | 2013 | 151 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2013 | 364 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5665 | 0.030 |
Why?
|
| GABA Agents | 1 | 2012 | 41 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2007 | 1878 | 0.030 |
Why?
|
| LLC-PK1 Cells | 1 | 2012 | 125 | 0.030 |
Why?
|
| Calcium | 2 | 2013 | 5726 | 0.030 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 167 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 1611 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2016 | 2265 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2013 | 426 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2011 | 110 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 290 | 0.020 |
Why?
|
| Sucrose | 1 | 2012 | 158 | 0.020 |
Why?
|
| Receptors, Kainic Acid | 1 | 2011 | 91 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14665 | 0.020 |
Why?
|
| Adrenergic Agents | 1 | 2011 | 74 | 0.020 |
Why?
|
| Age Factors | 2 | 2006 | 18401 | 0.020 |
Why?
|
| Hormones | 1 | 2015 | 867 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1993 | 367 | 0.020 |
Why?
|
| Chlordiazepoxide | 1 | 2010 | 42 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 398 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2013 | 897 | 0.020 |
Why?
|
| Alprazolam | 1 | 2010 | 102 | 0.020 |
Why?
|
| Hindlimb Suspension | 1 | 2011 | 75 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 8074 | 0.020 |
Why?
|
| GABA Modulators | 1 | 2010 | 109 | 0.020 |
Why?
|
| Mitochondria | 1 | 2023 | 3624 | 0.020 |
Why?
|
| Hyperalgesia | 1 | 2014 | 531 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 722 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 5778 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2009 | 12122 | 0.020 |
Why?
|
| Apomorphine | 1 | 2009 | 149 | 0.020 |
Why?
|
| Aphakia | 1 | 2009 | 26 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Receptors, Opioid | 1 | 1989 | 145 | 0.020 |
Why?
|
| Threonine | 1 | 2010 | 270 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2007 | 4013 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2012 | 942 | 0.020 |
Why?
|
| Food Preferences | 1 | 2012 | 398 | 0.020 |
Why?
|
| Animal Rights | 1 | 2008 | 10 | 0.020 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 1 | 2007 | 27 | 0.020 |
Why?
|
| Brain Waves | 1 | 2012 | 408 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2007 | 173 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1999 | 826 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2010 | 576 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2007 | 366 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 9414 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2011 | 733 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 1393 | 0.020 |
Why?
|
| Crime | 1 | 2008 | 202 | 0.020 |
Why?
|
| CLOCK Proteins | 1 | 2007 | 86 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2008 | 176 | 0.020 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2006 | 55 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2642 | 0.020 |
Why?
|
| Muscimol | 1 | 2006 | 70 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2008 | 296 | 0.020 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2006 | 169 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 86 | 0.020 |
Why?
|
| Sirolimus | 1 | 2013 | 1533 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4850 | 0.020 |
Why?
|
| GABA Agonists | 1 | 2006 | 105 | 0.020 |
Why?
|
| Primates | 1 | 2008 | 524 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 3592 | 0.020 |
Why?
|
| Lithium Compounds | 1 | 2007 | 223 | 0.020 |
Why?
|
| Esters | 1 | 2006 | 212 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2007 | 186 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2007 | 11070 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2007 | 409 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Methylation | 1 | 2007 | 1082 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 465 | 0.010 |
Why?
|
| Citalopram | 1 | 2007 | 402 | 0.010 |
Why?
|
| Amines | 1 | 2006 | 281 | 0.010 |
Why?
|
| Cricetulus | 1 | 2006 | 815 | 0.010 |
Why?
|
| Auditory Perception | 1 | 2009 | 583 | 0.010 |
Why?
|
| Young Adult | 2 | 2024 | 59196 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 2060 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4614 | 0.010 |
Why?
|
| Amides | 1 | 2006 | 449 | 0.010 |
Why?
|
| Cell Line | 2 | 2011 | 15599 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20092 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2007 | 1232 | 0.010 |
Why?
|
| Catheterization | 1 | 2008 | 1432 | 0.010 |
Why?
|
| Swine | 1 | 2012 | 5915 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2005 | 497 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2007 | 1035 | 0.010 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2001 | 74 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 1178 | 0.010 |
Why?
|
| Visual Perception | 1 | 2009 | 1385 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 574 | 0.010 |
Why?
|
| Haplotypes | 1 | 2006 | 2774 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2000 | 66 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 1249 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2002 | 1262 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1998 | 246 | 0.010 |
Why?
|
| Putamen | 1 | 1999 | 292 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 1999 | 389 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3777 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 1528 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2001 | 1084 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1998 | 1158 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 2275 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 2723 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 36430 | 0.010 |
Why?
|
| Quantitative Trait, Heritable | 1 | 1998 | 542 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2001 | 3097 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 16966 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7439 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 2648 | 0.010 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1993 | 2 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 950 | 0.010 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1993 | 63 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 6128 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 1526 | 0.010 |
Why?
|
| Basal Metabolism | 1 | 1993 | 161 | 0.010 |
Why?
|
| Diffusion | 1 | 1993 | 814 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12449 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11531 | 0.010 |
Why?
|
| Space Perception | 1 | 1993 | 465 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 7597 | 0.000 |
Why?
|
| Adolescent | 1 | 2015 | 88305 | 0.000 |
Why?
|
| Social Environment | 1 | 1989 | 1020 | 0.000 |
Why?
|
| Mutation | 1 | 2007 | 30044 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2006 | 54405 | 0.000 |
Why?
|
| United States | 1 | 2008 | 72317 | 0.000 |
Why?
|
| Dementia | 1 | 1993 | 2686 | 0.000 |
Why?
|
| Middle Aged | 1 | 2012 | 220774 | 0.000 |
Why?
|